Your browser doesn't support javascript.
loading
Reactive Oxygen Species Modulator 1 (Romo1) Predicts Poor Outcomes in Advanced Non-small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment ; : 141-149, 2017.
Article Dans Anglais | WPRIM | ID: wpr-6987
ABSTRACT

PURPOSE:

Reactive oxygen species modulator 1 (Romo1) is a key mediator of intracellular reactive oxygen species production. However, examination of the clinical usefulness of Romo1 in cancers has been limited. We evaluated the association of Romo1 expression with clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. MATERIALS AND

METHODS:

Romo1 expression in tumor tissue was examined by immunohistochemistry and evaluated by histological score. Survival analyses were performed according to Romo1 expression and the association between Romo1 expression and clinical parameters was evaluated.

RESULTS:

A total of 88 tumor specimens were analyzed. Significantly shorter median progression-free survival (PFS) was observed in the high Romo1 group compared with the low Romo1 group (4.5 months vs. 9.8 months, p < 0.001), and the median overall survival (OS) of the high Romo1 group was also significantly shorter than that of the low Romo1 group (8.4 months vs. 15.5 months, p < 0.001). Results of multivariate analyses showed significant association of high Romo1 expression with both poor PFS (hazard ratio [HR], 2.75; 95% confidence interval [CI], 1.71 to 4.44) and poor OS (HR, 3.99; 95% CI, 2.36 to 6.74). Results of the subgroup analysis showed a similar association regardless of tumor histology. Romo1 expression showed no association with any clinical parameter including age, sex, smoking status, stage, differentiation, or tumor histology.

CONCLUSION:

Romo1 overexpression was associated with poor response to treatment and shorter survival in advanced NSCLC patients treated with platinum-based chemotherapy. Romo1 could be a potential adverse predictive marker in this setting.
Sujets)

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Sujet Principal: Platine / Pronostic / Fumée / Immunohistochimie / Marqueurs biologiques / Fumer / Analyse multifactorielle / Espèces réactives de l&apos;oxygène / Carcinome pulmonaire non à petites cellules / Survie sans rechute Type d'étude: Étude pronostique Limites du sujet: Humains langue: Anglais Texte intégral: Cancer Research and Treatment Année: 2017 Type: Article

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Sujet Principal: Platine / Pronostic / Fumée / Immunohistochimie / Marqueurs biologiques / Fumer / Analyse multifactorielle / Espèces réactives de l&apos;oxygène / Carcinome pulmonaire non à petites cellules / Survie sans rechute Type d'étude: Étude pronostique Limites du sujet: Humains langue: Anglais Texte intégral: Cancer Research and Treatment Année: 2017 Type: Article